Show simple item record

dc.contributor.authorCoakley, Men_US
dc.contributor.authorGarcia-Murillas, Ien_US
dc.contributor.authorTurner, NCen_US
dc.date.accessioned2019-05-07T11:25:03Z
dc.date.issued2019-10en_US
dc.identifier.citationClinical cancer research : an official journal of the American Association for Cancer Research, 2019, 25 (20), pp. 6026 - 6034en_US
dc.identifier.issn1078-0432en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3221
dc.identifier.doi10.1158/1078-0432.ccr-19-0152en_US
dc.description.abstractAdvances in diagnosis and treatment have resulted in a high rate of survival for many patients with early-stage cancers. However, identifying who is at ongoing risk of relapse remains of high priority to direct subsequent adjuvant therapy. Multiple recent retrospective studies have shown that detection of tumor-derived materials in blood, in particular with circulating tumor DNA (ctDNA) analysis, can identify patients with residual disease before clinical or radiological evidence of metastatic disease, anticipating relapse with relatively high sensitivity and high specificity. We discuss how these emerging technologies are defining new subgroups of patients with "Molecular Residual Disease" and "Molecular Relapse." We outline how novel clinical trials in the adjuvant setting designed for these new subgroups of patients may improve selection for adjuvant therapies, and provide new surrogate endpoints that may allow for early registration of adjuvant therapies and novel clinical trial designs in the adjuvant setting. We discuss the current limitations of these techniques and the routes to clinical implementation.en_US
dc.formatPrint-Electronicen_US
dc.format.extent6026 - 6034en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserveden_US
dc.titleMolecular Residual Disease and Adjuvant Trial Design in Solid Tumors.en_US
dc.typeJournal Article
dcterms.dateAccepted2019-05-09en_US
rioxxterms.versionofrecord10.1158/1078-0432.ccr-19-0152en_US
rioxxterms.licenseref.startdate2019-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfClinical cancer research : an official journal of the American Association for Cancer Researchen_US
pubs.issue20en_US
pubs.notes12 monthsen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Molecular Oncology
pubs.publication-statusPublisheden_US
pubs.volume25en_US
pubs.embargo.terms12 monthsen_US
icr.researchteamMolecular Oncologyen_US
dc.contributor.icrauthorTurner, Nicholasen_US
dc.contributor.icrauthorGarcia-Murillas, Isaacen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record